Curated news and analysis on clinical trials, drug approvals, and medical research.
Ocular Therapeutix announced positive topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting its primary endpoint with statistically significant improvements in vision outcomes compared to aflibercept.
Benitec Biopharma will present interim clinical study results for BB-301 gene therapy in oculopharyngeal muscular dystrophy patients at the Muscular Dystrophy Association Conference on March 9, 2026, including 12-month and 24-month follow-up data.
Higher consumption of ultraprocessed food after cancer diagnosis is associated with increased rates of all-cause and cancer mortality, regardless of overall diet quality, according to a study of 802 cancer survivors.
Merck and Mayo Clinic announced a research collaboration allowing Merck to use AI and advanced analytics with Mayo's clinical and genomic datasets for drug discovery, initially focusing on dermatology, neurology, and gastroenterology.
iRegene Therapeutics has dosed the first U.S. patient in a Phase IIa trial of NouvNeu001 for Parkinson's disease and enrolled the first patient in a China trial of NouvNeu004 for Multiple System Atrophy.
Stoke Therapeutics presented long-term Dravet syndrome data showing up to 80% seizure reductions sustained through three years, outlined its Phase 3 EMPEROR trial design targeting mid-2027 data, and disclosed first patient dosing in its ADOA program.
Quantum computing breakthroughs in China and new quantum chemistry software demonstrate potential to accelerate drug discovery, materials science, and complex molecular simulations from weeks to minutes.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Novo Nordisk's experimental weight loss drug CagriSema achieved 23% weight loss after 84 weeks compared to 25.5% with Eli Lilly's tirzepatide in a head-to-head Phase 3 trial, sending Novo shares down 15% in Copenhagen.
Multiple institutional investors expanded their stakes in AstraZeneca during the third quarter of 2025, with the stock trading near its 52-week high and maintaining a "Moderate Buy" rating from analysts.
Millions of single-use GLP-1 pens may be improperly disposed of annually, while the supplement industry responds to nutritional gaps created by reduced food intake among users of drugs like Ozempic and Wegovy.
The FDA has filed Savara's biologics license application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a target action date of August 22, 2026.
An international research team has conducted the first comprehensive genetic study of cancer in domestic cats, identifying genetic changes that closely resemble those in human cancers and opening new perspectives for targeted therapies.
Trinity Biotech plc received two separate non-compliance notices from Nasdaq in February 2026 for failing to meet minimum bid price and market value requirements, with 180-day periods to regain compliance or face potential delisting.
Pharmaceutical and life sciences global capability centres in India are using AI, automation, and advanced analytics to reduce drug development timelines from 10-15 years to 9-13 years, while cutting R&D-to-launch costs from 20-30% to 15-25%.
China's brain-computer interface industry is rapidly commercializing with strong policy support, including an $165 million government fund and provincial medical pricing systems. The market is projected to reach $530 million in 2025 and over 120 billion yuan by 2040.
Zimbabwe rolled out lenacapavir, a twice-yearly HIV prevention injection, on Thursday for high-risk populations including sex workers and adolescent girls. The donor-supported program will initially reach 46,000 people across 24 sites.
Research published in Pediatric Research in February 2026 demonstrates that pediatric patients can successfully participate in cross-border clinical trials when language barriers are addressed through translation services and multilingual communication strategies.
NanoViricides is preparing to advance NV-387 into a Phase II clinical trial for Monkeypox in the Democratic Republic of Congo, with regulatory approval received and full funding secured through recent financings totaling approximately $6.2 million.
AbbVie announced a quarterly cash dividend of $1.73 per share, payable May 15, 2026. The company has increased its dividend by over 330 percent since 2013 and remains an S&P Dividend Aristocrat.
